Related references
Note: Only part of the references are listed.PubChem Substance and Compound databases
Sunghwan Kim et al.
NUCLEIC ACIDS RESEARCH (2016)
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
Richard Bayliss et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
In silico methods to address polypharmacology: current status, applications and future perspectives
Antonio Lavecchia et al.
DRUG DISCOVERY TODAY (2016)
Next generation ALK inhibitors and mechanisms of resistance to therapy
J. Gainor
ANNALS OF ONCOLOGY (2015)
Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description
Francesca Spyrakis et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2015)
The ABC of protein kinase conformations
Henrik Moebitz
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2015)
Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches
Osman A. Gani et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2015)
An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer
Xinghao Ai et al.
BIOCHIMIE (2015)
Structure-based design and synthesis of covalent-reversible inhibitors to overcome drug resistance in EGFR
Debjit Basu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Kinase hinge binding scaffolds and their hydrogen bond patterns
Li Xing et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Current kinase inhibitors cover a tiny fraction of fragment space
Hongtao Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Second generation ALK inhibitors in non-small cell lung cancer: Systemic review
Marie Viala et al.
BULLETIN DU CANCER (2015)
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Frederick H. Wilson et al.
CANCER CELL (2015)
Multi-Kinase Inhibitors
Laura Garuti et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
I. Watermann et al.
DIAGNOSTIC PATHOLOGY (2015)
Extending kinome coverage by analysis of kinase inhibitor broad profiling data
Edgar Jacoby et al.
DRUG DISCOVERY TODAY (2015)
The opportunities of mining historical and collective data in drug discovery
Anne Mai Wassermann et al.
DRUG DISCOVERY TODAY (2015)
Open Source Bayesian Models. 2. Mining a Big Dataset To Create and Validate Models with ChEMBL
Alex M. Clark et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2015)
Future options for ALK-positive non-small cell lung cancer
Daniela Iacono et al.
LUNG CANCER (2015)
Low-Quality Structural and Interaction Data Improves Binding Affinity Prediction via Random Forest
Hongjian Li et al.
MOLECULES (2015)
ChEMBL web services: streamlining access to drug discovery data and utilities
Mark Davies et al.
NUCLEIC ACIDS RESEARCH (2015)
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Helen Y. Zou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Beware of docking!
Yu-Chian Chen
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Target prediction utilising negative bioactivity data covering large chemical space
Lewis H. Mervin et al.
JOURNAL OF CHEMINFORMATICS (2015)
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
Luca Mologni et al.
ONCOTARGET (2015)
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
Paolo Maione et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Exploring the Scaffold Universe of Kinase Inhibitors
Ye Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
Jeff Engle et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2014)
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
Claudia Fumarola et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c] pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors
Sebastien Tardy et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases
H. Patterson et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Targeting the MET gene for the treatment of non-small-cell lung cancer
F. Gelsomino et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles
Jing Tang et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Progress in the Analysis of Multiple Activity Profile of Screening Data Using Computational Approaches
Vicente F. Kuyoc-Carrillo et al.
DRUG DEVELOPMENT RESEARCH (2014)
Emerging protein kinase inhibitors for non-small cell lung cancer
Stephen V. Liu et al.
EXPERT OPINION ON EMERGING DRUGS (2014)
Protein kinase inhibitors to treat non-small-cell lung cancer
Gabriele Minuti et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Beware of Machine Learning-Based Scoring Functions-On the Danger of Developing Black Boxes
Joffrey Gabel et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
Scaffold mining of kinase hinge binders in crystal structure database
Li Xing et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2014)
Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib
Qinhua Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
Norihiro Yamaguchi et al.
LUNG CANCER (2014)
PubChem BioAssay: 2014 update
Yanli Wang et al.
NUCLEIC ACIDS RESEARCH (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Adam S. Crystal et al.
SCIENCE (2014)
Advances in kinase targeting: current clinical use and clinical trials
Mathias Rask-Andersen et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors
Balint Szokol et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Novel 2,4-Diarylanninopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities
Zhiqing Liu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Kevin Becker et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Review of the current targeted therapies for non-small-cell lung cancer
Kim-Son H. Nguyen et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Resistant mutations in CML and Ph+ALL - role of ponatinib
Geoffrey D. Miller et al.
BIOLOGICS-TARGETS & THERAPY (2014)
Combined Analysis of Phenotypic and Target-Based Screening in Assay Networks
S. Joshua Swamidass et al.
JOURNAL OF BIOMOLECULAR SCREENING (2014)
Non-small-cell lung cancers: a heterogeneous set of diseases
Zhao Chen et al.
NATURE REVIEWS CANCER (2014)
ALK and crizotinib: after the honeymoon... what else? Resistance mechanisms and new therapies to overcome it
Christian Rolfo et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2014)
De Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding Fragments
Robert Urich et al.
ACS CHEMICAL BIOLOGY (2013)
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery
Yinghong Gao et al.
BIOCHEMICAL JOURNAL (2013)
What general conclusions can we draw from kinase profiling data sets?
Jeffrey J. Sutherland et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2013)
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors
Dengyou Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Evaluating the Predictivity of Virtual Screening for Abl Kinase Inhibitors to Hinder Drug Resistance
Osman A. B. S. M. Gani et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
John R. Goffin et al.
CLINICAL THERAPEUTICS (2013)
p38 Mitogen-Activated Protein Kinase Inhibitors: A Review on Pharmacophore Mapping and QSAR Studies
Rahul P. Gangwal et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Shifting from the single to the multitarget paradigm in drug discovery
Jose L. Medina-Franco et al.
DRUG DISCOVERY TODAY (2013)
Selectivity Data: Assessment, Predictions, Concordance, and Implications
Cen Gao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Ability of the Met Kinase Inhibitor Crizotinib and New Generation EGFR Inhibitors to Overcome Resistance to EGFR Inhibitors
Shigeki Nanjo et al.
PLOS ONE (2013)
Combining Machine Learning Systems and Multiple Docking Simulation Packages to Improve Docking Prediction Reliability for Network Pharmacology
Kun-Yi Hsin et al.
PLOS ONE (2013)
Aminopyridyl/Pyrazinyl Spiro[indoline-3,4′-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors
Jingrong Li et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool
Espen Aberg et al.
BIOLOGICAL CHEMISTRY (2012)
Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors
Dengyou Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
A Comparative Assessment of Ranking Accuracies of Conventional and Machine-Learning-Based Scoring Functions for Protein-Ligand Binding Affinity Prediction
Hossam M. Ashtawy et al.
IEEE-ACM TRANSACTIONS ON COMPUTATIONAL BIOLOGY AND BIOINFORMATICS (2012)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Youngwook Kim et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Takayuki Nakagawa et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
Arvin C. Dar et al.
NATURE (2012)
Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition
P. Jake Slavish et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Irreversible Protein Kinase Inhibitors
L. Garuti et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met
Qing-Qing Xie et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197
Sudharshan Eathiraj et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Trends in Kinase Selectivity Insights for Target Class-Focused Library Screening
Shana L. Posy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
Emeline Leproult et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Navigating the kinome
James T. Metz et al.
NATURE CHEMICAL BIOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors
Xianming Deng et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Structure-guided expansion of kinase fragment libraries driven by support vector machine models
Jon A. Erickson et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking
Pedro J. Ballester et al.
BIOINFORMATICS (2010)
Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors
Hiroki Nishii et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Takaaki Sasaki et al.
CANCER RESEARCH (2010)
Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry
Lisa M. Wodicka et al.
CHEMISTRY & BIOLOGY (2010)
Predicting Polypharmacology by Binding Site Similarity: From Kinases to the Protein Universe
Francesca Milletti et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
Richard Morphy
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors
Sergei L. Timofeevski et al.
BIOCHEMISTRY (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery
Paul Bamborough et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Kinase-likeness and kinase-privileged fragments: Toward virtual polypharmacology
Alex M. Aronov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Design, synthesis, and biological evaluation of potent c-Met inhibitors
Noel D. D'Angelo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
Treatment for chronic myelogenous leukemia: the long road to imatinib
Tony Hunter
JOURNAL OF CLINICAL INVESTIGATION (2007)
Receptor tyrosine kinases: mechanisms of activation and signaling
Stevan R. Hubbard et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Structure and chemical inhibition of the RET tyrosine kinase domain
Phillip P. Knowles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases - Implications for clinical resistance in targeted cancer treatment
N von Bubnoff et al.
CELL CYCLE (2005)
A small molecule-kinase interaction map for clinical kinase inhibitors
MA Fabian et al.
NATURE BIOTECHNOLOGY (2005)
Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity
CE Fitzgerald et al.
NATURE STRUCTURAL BIOLOGY (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
PLS-regression:: a basic tool of chemometrics
S Wold et al.
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS (2001)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
